l Sunday, May 5, 1996 Podium Session 3 1:00 pm to 3:00 pm I

NOVEL APPROACHES IN ASSESSMENT A N D TREATMENT OF BLADDER CANCER Room 224 E-H, Orange County Convention Center

Moderators: Donald L. Lamm, Morgantown, WV Edward M. Messing, Rochester, NY

(Note: all presentations are 7 minutes in length.)

1:00

1:10

1:20

1:30

1:40

1:50

2:00

#34

#35

#36

#37

#38

#39

#40

Interleukin-8 (11.-8) expression in the urine after BCG therapy: a potential predictor of tumor recurrence and progression.

George N. Thalmann, B. Dewald, Marco Baggiolini and Urs E. Studer, Berne, Switzerland (Presented by Dr. Thalmann).

Lactobacillus casei (LC) immunotherapy of murine bladder cancer (MBT2).

Dale R. Riggs, Jean I. DeHaven and Donald L. Lamm, Morgantown, WV (Presented by Dr. Lamm).

Reverse transcriptase polymerase chain reaction based assay to detect circulating bladder cancer cells.

B. Mayer Grob, Sai L. Su, Warren W.D. Heston and William R. Fair, New York, NY (Presented by Dr. Grob).

Continuous intraperitoneal (IP) infusion of inter- leukin-2 (IL-2) in the treatment of bladder cancer.

William A. Larchian, Smita K. Nair and Eli Gilboa, Durham, NC; Warren D.W. Heston and William R. Fair, New York, NY (Presented by Dr. Larchian).

Rationale and development of retinoblastoma (Rb) tumor suppressor gene therapy for bladder cancer.

John D. Seigne, Shi-Xue Hu, Chen-Te Kong, Yunli Zhou, William F, Benedict and Hong-Ji Xu, Houston, TX (Presented by Dr. Seigne).

Liposome mediated gene therapy in bladder cancer utilizing interleukin-2 (11_-2) and B7.

William A. Larchian, Smita K. Nair and Eli Gilboa, Durham, NC; Warren D.W. Heston and William R. Fair, New York, NY (Presented by Dr. Larchian).

Inhibition of transitional cell carcinoma growth by a peptide mimetic of an anti-Neu monoclonal antibody complementarity-determining region.

S. Bruce Malkowicz, Norman Peterson, Juanita Thomas, Terence McGarvey and Mark 1. Greene, Philadelphia, PA (Presented by Dr. Malkowicz).

2:10 #41

2:20

2:30

2:40

2:50

#42

#43

#44

#45

Induction of fibronectin expression in transitional carcinoma cell lines by post-TURBT urine: time course and TGF-[31 dependence.

David Ladehof, Yong Xu and William A. See, Iowa City, IA (Presented by Dr. See).

Adenovirus-mediated suicide gene therapy for experimental bladder cancer.

Mark A. Sutton, Scott A. Berkman, Trong Dang, Shu-Hsia Chen, Andreas Block, David R. Rowley, Savio L.C. Woo and Seth P. Lerner, Houston, TX (Presented by Dr. Sutton).

Bladder tumor production in female Wistar rats: a new tumor model for transitional cell carci- noma.

james Hendricks, David L. Bowers, John Connor, Brenda Mallory, Min Wei Chen, Kathleen O'Toole and Steven A. Kaplan, New York, NY (Presented by Dr. Bowers).

Predictive value of aberrations of chromosome 9 following bacillus calmette-guerin (BCG) therapy in bladder cancer.

Leon L. Wheeless, Josephine F. Morreale, Mary J. O'Connell, Rujing Han, Zihong Yang, Jay E. Reeder, Irwin N. Frank and Edward M. Messing, Rochester, NY (Presented by Dr. Wheeless).

Determination and reversal of multidrug resis- tance in intraveslcal chemotherapy.

Peter Duffy, Matthew Hayes, Alan Cooper, Christopher Smart and Brian Birch, Southampton, UK (Presented by Dr. Duffy).

74